A Comparison Between the Aysis® Cs2 (General Electrics) Ventilator in EtControl® Mode and the Perseus® A 500 (Dräger) in VaporView® Mode on Maniability and Consumption of Desflurane

Desflurane Clinical Trial

— ConsoHalo  

Official title:

A Comparison Between the Aysis® Cs2 (General Electrics) Ventilator in EtControl® Mode and the Perseus® A 500 (Dräger) in VaporView® Mode on Maniability and Consumption of Desflurane

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02427971
• Other study ID #: 2014-A01476-41
• Status: Recruiting
• Phase: N/A
• First received: April 15, 2015
• Last updated: April 27, 2015
• Start date: January 2015
• Est. completion date: April 2015

Study information

• Verified date: April 2015
• Source: Saint Antoine University Hospital
• Contact: n/a
• Is FDA regulated: No
• Health authority: France: Committee for the Protection of Personnes
• Study type: Observational

Clinical Trial Summary

The Aysis® Cs2 ventilator offers an automated control of end-tidal inhalation anesthetic concentration, the EtControl® mode. A low Fresh Gas Flow (FGF) (0.5L/min) is kept during the maintenance of the anesthesia, decreasing the expensive consumption of halogenated agents.

The Perseus® A 500 offers a VaporView® mode that gives the evolution of inspired (Fi) and end-tidal (Fe) fractions of halogenated agents for 20 minutes based on the delivered fraction (Fd). FGF remains adjusted manually by the practitioner. This mode also makes it possible to maintain a low FGF (0.5 L/min), provided the halogen Fd is set to maintain a steady Fe curve.

The goal of this work was to compare the maniability of the intraoperative administered concentrations and the consumption of Desflurane between these 2 modalities of administration.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 60
• Est. completion date: April 2015
• Est. primary completion date: April 2015
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• patients undergoing a general anesthesia for intra abdominal surgery during more than one hour

• ASA 1or 2

Exclusion Criteria:

• contraindication to halogenated agent

• thoracic surgery

• no french speaking

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• Anesthetics Agent
• Consumption
• Desflurane
• Inhalation

Locations

Country	Name	City	State
France	Hôpital Saint-Antoine	Paris

Sponsors (1)

Lead Sponsor	Collaborator
Saint Antoine University Hospital

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Consumption of Desflurane between these 2 modalities of administration.	Des consumption was measured by micrometric weighing of the vaporizer before and after general anesthesia and a milliliter per min consumption was calculated	Time of general anesthesia (1h minimum up to 12h)	No
Secondary	Comparison of inspired (Fi) and end-tidal (Fe) fractions of halogenated evolution		Time of general anesthesia (1h minimum up to 12h)	No
Secondary	Anesthesia depth monitoring by BIS		Time of general anesthesia (1h up to 12h)	No
Secondary	Hemodynamic stability	Number of cardiovascular event which required an intervention; Vasopressive drug; Antihypertensive drug; modification of the Desflurane end-tidal (Fe) fraction	Time of general anesthesia (1h minimum up to 12h)	Yes